Metabolic Myopathies: Update 2009
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Metabolic myopathies are inborn errors of metabolism that result in impaired energy production due to defects in glycogen, lipid, mitochondrial, and possibly adenine nucleotide metabolism. Fatty acid oxidation defects (FAOD), glycogen storage disease, and mitochondrial myopathies represent the 3 main groups of disorders, and some consider myoadenylate deaminase (AMPD1 deficiency) to be a metabolic myopathy. Clinically, a variety of neuromuscular presentations are seen at different ages of life. Newborns and infants commonly present with hypotonia and multisystem involvement (liver and brain), whereas onset later in life usually presents with exercise intolerance with or without progressive muscle weakness and myoglobinuria. In general, the glycogen storage diseases result in high-intensity exercise intolerance, whereas the FAODs and the mitochondrial myopathies manifest predominately during endurance-type activity or under fasted or other metabolically stressful conditions. The clinical examination is often normal, and testing requires various combinations of exercise stress testing, serum creatine kinase activity and lactate concentration determination, urine organic acids, muscle biopsy, neuroimaging, and specific genetic testing for the diagnosis of a specific metabolic myopathy. Prenatal screening is available in many countries for several of the FAODs through liquid chromatography-tandem mass spectrometry. Early identification of these conditions with lifestyle measures, nutritional intervention, and cofactor treatment is important to prevent or delay the onset of muscle weakness and to avoid potential life-threatening complications such as rhabdomyolysis with resultant renal failure or hepatic failure. This article will review the key clinical features, diagnostic tests, and treatment recommendations for the more common metabolic myopathies, with an emphasis on mitochondrial myopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Romijn, J. A., Coyle, E. F., Sidossis, L. S., Gastaldelli, A., Horowitz, J. F., Endert, E., & Wolfe, R. R. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.265.3.e380 · Cited by 1,747
Threshold Effect and Tissue Specificity
Rossignol, R., Malgat, M., Mazat, J.-P., & Letellier, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.47.33426 · Cited by 288
The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients
Taivassalo, T. (2003) · Brain · doi:10.1093/brain/awg028 · Cited by 282
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Self-citationGenetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
Self-citationCreatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Self-citationMatthews, P. M., Allaire, C., Shoubridge, E. A., Karpati, G., Carpenter, S., & Arnold, D. L. (1991) · Neurology · doi:10.1212/wnl.41.1.114 · Cited by 121 · cited 1×
“Phosphorus ((31)P) MRS has also been used to demonstrate an increased reliance on phosphocreatine hydrolysis or a delay in the postexercise phosphocreatine recovery.(66,67) EMG may show a characteristic pattern of a myopathic process or a mixed myopathic and neuropathic pattern but are most often normal.”
MethodEffects of Dietary Fat on Muscle Substrates, Metabolism, and Performance in Athletes
VOGT, M., PUNTSCHART, A., HOWALD, H., MUELLER, B., MANNHART, C., GFELLER-TUESCHER, L., MULLIS, P., & HOPPELER, H. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000069336.30649.bd · Cited by 120
Exercise and training in mitochondrial myopathies
TAIVASSALO, T., & HALLER, R. G. (2005) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000177446.97671.2a · Cited by 106
Dietary carbohydrate, muscle glycogen content, and endurance performance in well-trained women
Walker, J. L., Heigenhauser, G. J. F., Hultman, E., & Spriet, L. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.6.2151 · Cited by 105
Cited by
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Squires, R. H., Ng, V., Romero, R., Ekong, U., Hardikar, W., Emre, S., & Mazariegos, G. V. (2014) · Hepatology · doi:10.1002/hep.27191 · Cited by 254
Perspectives on Exertional Rhabdomyolysis
Rawson, E. S., Clarkson, P. M., & Tarnopolsky, M. A. (2017) · Sports Medicine · doi:10.1007/s40279-017-0689-z · Cited by 133
Self-citationThe Psychiatric Presentation of Mitochondrial Disorders in Adults
Anglin, R. E., Tarnopolsky, M. A., Mazurek, M. F., & Rosebush, P. I. (2012) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.11110345 · Cited by 77
Self-citation
Metadata
- Authors
- van Adel, B. A., & Tarnopolsky, M. A.
- Venue
- Journal of Clinical Neuromuscular Disease
- Published
- 2009-03
- Volume
- 10
- Issue
- 3
- Pages
- 97-121
- ISSN
- 1522-0443 (ISSN-L)
- OpenAlex
- W2085863956
- Cited by
- 107
- References
- 15
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Myopathies: Update 2009. https://app.cochat.ai/papers/10.1097/cnd.0b013e3181903126
- The paper
- van Adel, B. A., & Tarnopolsky, M. A. (2009). Metabolic Myopathies: Update 2009. Journal of Clinical Neuromuscular Disease. https://doi.org/10.1097/cnd.0b013e3181903126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.